PSS World Medical
The 10-second takeaway
For the quarter ended Dec. 30 (Q3), PSS World Medical missed slightly on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and earnings per share grew.
Gross margins improved, operating margins contracted, and net margins were steady.
PSS World Medical recorded revenue of $521.8 million. The seven analysts polled by S&P Capital IQ predicted revenue of $530.0 million. Sales were 3.5% higher than the prior-year quarter's $496.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $0.37. The earnings estimates compiled by S&P Capital IQ predicted $0.37 per share on the same basis. GAAP EPS of $0.38 for Q2 were 8.6% higher than the prior-year quarter's $0.35 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 32.3%, 130 basis points better than the prior-year quarter. Operating margin was 6.6%, 20 basis points worse than the prior-year quarter. Net margin was 3.8%, about the same as the prior-year quarter.
Next quarter's average estimate for revenue is $539.6 million. On the bottom line, the average EPS estimate is $0.39.
Next year's average estimate for revenue is $2.13 billion. The average EPS estimate is $1.44.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 61 members out of 65 rating the stock outperform, and four members rating it underperform. Among 30 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give PSS World Medical a green thumbs-up, and none give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PSS World Medical is hold, with an average price target of $25.13.
Over the decades, small-cap stocks like PSS World Medical have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add PSS World Medical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.